Raise closed, search for fresh raises on Seedstage

Bridgewater, NJ

Expanding access to a wearable, AI-driven solution for chronic pain and neuromuscular disorders through global partnerships and healthcare system integration.

• Breakthrough technology: FDA-authorized, AI-driven wearable device for noninvasive treatment.
• Established partnerships: Used by hospitals like Mayo Clinic, Mount Sinai, and Weill Cornell.
• Insurance reimbursement: Treatments covered by Medicare and major insurers.
• Global scaling strategy: Expanding to international markets and employer health programs.
• Proven patient benefits: Demonstrated improvements in pain reduction and muscle function.

JOGO is raising funds to scale its noninvasive, AI-powered wearable solution for treating chronic pain and neuromuscular disorders. The company offers an alternative to conventional treatments such as pharmaceuticals and surgery, targeting a significant gap in healthcare with a safe, accessible, and clinically validated method. With FDA market authorization and coverage by Medicare and commercial insurance, JOGO’s device and app leverage neuroplasticity to deliver measurable outcomes for conditions like stroke recovery, migraines, Parkinson’s, urinary incontinence, and cancer-related pain. This capital will enable JOGO to extend its direct-to-patient model through hospital referrals and expand its leasing model to healthcare systems globally.

With contracts already in place and ongoing partnerships with major medical institutions, JOGO plans to broaden its impact by leasing devices to regional specialists and integrating its technology into corporate benefits programs. The company is pursuing a global footprint and long-term goal of becoming the first-line treatment for chronic pain. The funds raised will support this growth strategy, helping JOGO reach more patients and physician offices around the world. By positioning itself within a $600B+ projected market, JOGO aims to fundamentally reshape the standard of care in pain management and neuromuscular rehabilitation.

Company Info

JOGO Health offers a noninvasive, AI-driven wearable and app platform for treating chronic pain and neuromuscular conditions.

JOGO Health provides a noninvasive, drug-free solution for chronic pain and neuromuscular disorders through its wearable device and mobile app. Using AI-driven technology and neuroplasticity principles, the system supports treatment for conditions like urinary incontinence, migraines, Parkinson’s disease, stroke recovery, and pelvic floor disorders. The solution is safe for children and pregnant women and addresses conditions often underserved by traditional treatments.

JOGO operates through direct patient sales and B2B leasing to hospitals and clinics, with treatments reimbursable by Medicare and commercial insurance. Partner institutions include Mayo Clinic, Mount Sinai, and Brigham and Women’s Hospital. The company is expanding globally and has begun direct sales to employers. Positioned in a healthcare market projected to exceed $600B by 2030, JOGO aims to become a first-line treatment, with a vision to place its devices in over one million medical and workplace settings.